MADISON, Wis., Sept. 19, 2017
MADISON, Wis., Sept. 19, 2017 /PRNewswire/ -- Today, Propeller Health released the results from three new asthma and COPD studies presented last week at the European Respiratory Society International Congress (ERS) in Milan, Italy. The five-day event is the world's largest respiratory health meeting.
The company shared interim results on the feasibility and clinical impact of a digital health intervention (Propeller) among a Medicare population with COPD. This study monitored 201 participants over a six-month period, and demonstrated a significant decrease in short-acting bronchodilator (SABA) use and an increase in symptom-free days.
In a second presentation, Propeller shared findings from a two-year study investigating frequency and timing of SABA use among 3,373 asthma patients. Objective data captured from Propeller's passive sensors illustrates how granular data on medication use can illuminate new patterns of risk and impairment.
On Wednesday, Propeller presented data from an ongoing program with Dignity Health, where participants experienced significant reductions in acute asthma-related healthcare utilization, including ED visits, hospitalization and inpatient days.
"The research presented at ERS from Dignity Health demonstrates how Propeller may reduce the number of resource intensive events such as asthma-related hospitalization and ED events and reduce the disease burden for both patients and society," explained Dr. David Stempel, Propeller SVP of Medical and Clinical Affairs.
"We're excited to share these new data about the clinical utility of digital health, and to take part in an active and enthusiastic conversation in Milan about how our technology can be put to work by physicians across Europe," said David Van Sickle, Propeller CEO. "We look forward to continuing to contribute to the scientific study of the benefits of digital medicines and connected care in the management of asthma and COPD."
Propeller has 34 peer-reviewed publications and abstracts to date, with several studies currently in review. Propeller is heading to Boston and Toronto next month to present at the Connected Health Conference and the CHEST Annual Meeting.
Propeller empowers people with asthma and COPD to live measurably better lives. In 2010 Propeller set out to modernize respiratory medicine, empower people to minimize the impact of asthma and COPD on their daily lives, and connect them to their physicians, environment and community. Propeller's information-powered approach to respiratory management guides physicians and patients to the optimal path of therapy for each individual. With connected inhalers, digital interfaces, and real time personalized insights, participants receive personal guidance and expert direction anytime. Backed by 3M Ventures (NYSE: MMM), SR One, Hikma Ventures (LON: HIK), Safeguard Scientifics (NYSE: SFE), Social Capital and other investors, Propeller has been used by patients with asthma or COPD in over 45 commercial programs across the US at major healthcare systems, payers, employers and other commercial partners. The company has been recognized as the recipient of the American Telemedicine Association's 2016 President's Award for Innovation in Remote Healthcare, as one of the world's Most Innovative Companies by Fast Company, and as one of the top "Fierce 15" medical device companies in 2015 by FierceMedicalDevices. For more information visit: www.propellerhealth.com
SOURCE Propeller Health